featured
Improved Outcomes With Combined Nivolumab and Ipilimumab vs Ipilimumab Alone in Patients With Advanced Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Combined Nivolumab and Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Melanoma: 2-Year Overall Survival Outcomes in a Multicentre, Randomised, Controlled, Phase 2 Trial
Lancet Oncol 2016 Sep 09;[EPub Ahead of Print], FS Hodi, J Chesney, AC Pavlick, C Robert, KF Grossmann, DF McDermott, GP Linette, N Meyer, JK Giguere, SS Agarwala, M Shaheen, MS Ernstoff, DR Minor, AK Salama, MH Taylor, PA Ott, C Horak, P Gagnier, J Jiang, JD Wolchok, MA PostowFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.